Special biological issues in the management of women with schizophrenia

Jayashri Kulkarni, Emmy Gavrilidis, Emily Hayes, Victoria Heaton, Roisin Worsley
In: Expert Review of Neurotherapeutics · 2012 · vol. 12(7) , pp. 823–833 · doi:10.1586/ern.12.62 · PMID:22853790 · W2032408507
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This review explores the scientific basis for estradiol as an adjunctive therapy for schizophrenia in women, considering gender differences and the impact of the reproductive life cycle.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Schizophrenia is a debilitating and pervasive mental illness with devastating effects on psychological, cognitive and social wellbeing, and for which current treatment options are far from ideal. Gender differences and the influence of the female reproductive life cycle on the onset, course and symptoms of schizophrenia and the discovery of estrogen's remarkable psychoprotective properties in animal models led to the proposal of the 'estrogen protection hypothesis' of schizophrenia. This has fueled the recent successful investigation of estradiol as a potential adjuvant therapeutic agent in the management of schizophrenia in women. This review explains the scientific rationale behind the estrogen hypothesis and how it can be clinically utilized to address concerns unique to the care of women with schizophrenia.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (100)

SciLite annotations

organisms 4
noordeloos 2009062 rodents noordeloos 2009062 noordeloos 2009062
chemicals 4
estrogen estrogen estradiol estrogen

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0 · commercial use OK